LiverSpheroidsforDrug-InducedLiverInjury(DILI)Prediction

Why It Matters

Drug-induced liver injury (DILI) is a leading cause of acute liver failure and drug attrition in clinical trials, costing the pharmaceutical industry billions and endangering patients. Liver spheroids could provide a more accurate, high-throughput screening tool, identifying hepatotoxic compounds earlier in development, thus reducing drug failure rates and improving patient safety. Pharmaceutical companies, drug regulators, and patients benefit from safer, more effective drugs; contract research organizations relying on outdated models might need to adapt. Challenges include standardizing spheroid production for consistency, integrating them into high-throughput automated screening workflows, and gaining broader regulatory acceptance as a validated alternative to animal testing. Widespread adoption in preclinical drug screening is expected within 3-7 years, as the technology matures and validation data accumulates. Companies like InSphero (Switzerland) and Sekisui XenoTech (US) are market leaders, alongside significant academic research. A second-order consequence is the potential to rapidly identify environmental toxins and food additives that pose liver risks, leading to more stringent public health regulations and product safety standards.